Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Wells Fargo analyst Stephen Baxter maintained Cardinal Health with an Equal-Weight and raised the price target from $135 to ...

The global situation right now is a moving target, forcing many business owners to hope for the best and prepare for the ...

Cardinal Health (NYSE:CAH – Get Free Report) had its price target upped by equities researchers at Wells Fargo & Company from ...

Q2 2025 Earnings Call Transcript January 30, 2025 Cardinal Health, Inc. beats earnings expectations. Reported EPS is $1.93, ...

Draped in Mexican and Salvadoran flags, roughly 1,000 demonstrators gathered near City Hall shortly before noon, blocking ...

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardinal Health (CAH – Research Report) and Apyx ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its ...

Cardinal Health Inc. closed 5.65% below its 52-week high of $132.84, which the company achieved on January 30th.